Lisocabtagene maraleucel

Real-world data on CD19-directed CAR T-cell therapy lisocabtagene maraleucel (liso-cel) in relapsed/refractory large B-cell lymphoma (LBCL) show similar safety and efficacy to pivotal trials. Median progression-free survival (PFS) and overall survival (OS) were not reached (NR) at 6.4 months follow-up. Objective response rate (ORR) was 84%, with a complete response (CR) rate of 70%. Liso-cel demonstrated deep responses in a broad patient cohort, supporting its use as a second-line treatment regardless of age.

Real-world data on liso-cel (Breyanzi) in relapsed/refractory large B-cell lymphoma (LBCL) showed safety and efficacy comparable to pivotal trials, with median progression-free survival (PFS) and overall survival (OS) not reached (NR) at 6.4 months follow-up. Objective response rate (ORR) was 84% with a complete response (CR) rate of 70%, and median duration of response (DOR) was NR. These results support liso-cel as a second-line standard-of-care treatment for LBCL.

Liso-cel therapy in relapsed/refractory large B-cell lymphoma showed consistent PFS and OS with prior trials, with median PFS and OS not reached at 6.4 months follow-up. ORR was 84% with a CR rate of 70%, and median DOR was NR. Safety profile consistent with previous reports, with most patients experiencing low-grade CRS and ICANS.

Nicole Lamanna discussed the progression in CLL patients with covalent BTK inhibitors and venetoclax, emphasizing the need for new treatments. She highlighted clinical trials and CAR T-cell therapy options, including the TRANSCEND CLL 004 trial with lisocabtagene ciloleucel, and the CaDAnCE-101 trial with BGB-16673. Lamanna also presented the EPCOR trial with epcoritamab-bysp, suggesting bispecific antibodies as potential next steps for CLL treatment.

Second Circuit questions Bristol-Myers Squibb's alleged misleading of investors about a payout dependent on FDA approval of cancer drugs during Covid-19 pandemic. Investors claim Bristol-Myers delayed approvals to avoid payments, while Bristol-Myers argues disruptions from Covid-19 caused delays. Lower court dismissed the case for lack of evidence of intent to deceive.

In a large prospective study, outpatient CAR-T therapy for relapsed or refractory large B-cell lymphoma (LBCL) showed high efficacy with 80% objective response and 54% complete response, and minimal serious side effects. The study, published in *Blood Advances*, demonstrated the feasibility of community-based outpatient CAR-T treatment, potentially expanding patient access and reducing hospital stays.

CAR T-cell therapy emerges as a promising treatment for relapsed or refractory DLBCL, offering personalized precision medicine. Early use can improve outcomes, reduce treatment burden, and enhance overall survival. However, accessibility challenges due to manufacturing complexity and high costs persist.

Lisocabtagene maraleucel (liso-cel) improved response outcomes in relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients, with consistent results across high-risk features. Lower tumor burden and fewer prior treatments correlated with better responses. The objective response rate (ORR) and complete response (CR) rates varied by disease characteristics, but overall, liso-cel showed efficacy even in high-risk patients. Inflammatory markers, bulky disease, and lower creatine clearance rates increased the risk of neurological toxicity.